

IFW

CERTIFICATE OF MAILING BY FIRST CLASS MAIL (37 CFR 1.8)

Applicant(s): **Gudmundsson et al.**

Docket No.

PU4959USW

Application No.

10/530,101

Filing Date

April 1, 2005

Examiner


Customer No.

23347

Group Art Unit

1614

Invention: **Therapeutic Compounds Based on Pyrazolopyridine Derivatives**



I hereby certify that this **Supplemental IDS w/references**

(Identify type of correspondence)

is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope

addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

August 31, 2005

(Date)

Valerie L. Phillips

(Typed or Printed Name of Person Mailing Correspondence)

A handwritten signature in cursive script that reads "Valerie L. Phillips".

(Signature of Person Mailing Correspondence)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Gudmundsson et al.
 Serial No.: 10/530,101 Group Art Unit:
 File Date: April 1, 2005 Examiner: 1614
 For: Therapeutic Compounds Based on Pyrazolopyridine Derivatives

Director of the U.S. Patent and Trademark Office
 P.O. Box 1450
 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

- ☒ Copies of the references are enclosed:
☐ Copies of the references were submitted in parent application _____ (37 CFR 1.98(d))
☐ A copy of the International Search Report which issued on International Application No. _____ is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.
- A. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).
- OR
- ☐ **The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action or after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).**
- B. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:
- (1) a final action under § 1.113 or
 - (2) a notice of allowance under § 1.311, whichever occurs first.
- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).
- C. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- ☐ The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.

☒ Please charge any required fees to Deposit Account No.07-1392.

☐ A duplicate copy of this paper is attached.

Respectfully Submitted,



Lorie Ann Morgan

Registration No. 38,181

Date: *31 Aug 05*
GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-8222
Facsimile: (919) 483-7988

EXAMPLE-1449 INFORMATION DISCLOSURE STATEMENT SEP 06 2005 UNITED STATES PATENT & TRADEMARK OFFICE	ATTORNEY DOCKET NO. PU4959USW	SERIAL NO. 10/530,101
	APPLICANT: GUDMUNDSSON et al.	
	FILING Date: April 1, 2005	GROUP 1614

U.S. PATENT DOCUMENTS

Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	1	5,498,774	Mar. 12, 1996	Mitsudera et al.			
	2	5,990,148	Nov. 23, 1999	Isakson et al.			
	3	5,700,816	Dec. 23, 1997	Isakson et al.			
	4	6,136,839	Oct. 24, 2000	Isakson et al.			
	5	5,552,422	Sep. 3, 1996	Gauthier et al.			
	6	5,300,478	Apr. 5, 1994	Michaely et al.			
	7	4,985,444	Jan. 15, 1991	Shiokawa et al.			
	8	5,296,490	Mar. 22, 1994	Shiokawa et al.			
	9	5,155,114	Oct. 13, 1992	Shiokawa et al.			

Continue on page 2

FOREIGN PATENT DOCUMENTS

		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
	10	WO 99 64419	Dec. 16, 1999	WIPO			
	11	WO 98 56377	Dec. 17, 1998	WIPO			
	12	WO 02 16359	Feb. 28, 2002	WIPO			
	13	EP 0 379 979	Aug. 1, 1990	Europe			
	14	WO 02 066481	Aug. 29, 2002	WIPO			
	15	WO 01 14375	Mar. 1, 2001	WIPO			
	16	EP 0 404 190 A1	June 22, 1990	Europe			
	17	EP 0 404 190 B1	June 22, 1990	Europe			
	18	WO 91 19497	Dec. 26, 1991	WIPO			
	19	WO 96 41625	Dec. 27, 1996	WIPO			
	20	WO 96 41626	Dec. 27, 1996	WIPO			
	21	WO 96 41645	Dec. 27, 1996	WIPO			
	22	WO 91 00092	Jan. 10, 1991	WIPO			
	23	WO 95 00501	Jan. 5, 1995	WIPO			

Continue on page 2

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

	24	Vane, J. et al. "Towards a Better Aspirin." Nature, Vol. 367, Jan. 20, 1994, pgs. 215-216.
	25	Carter, J. et al. "Recently Reported Inhibitors of Cyclooxygenase-2." Exp. Opin. Ther. Patents (1998), 8(1), pgs. 21-29.
	26	Talley, JJ., "Review, Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis, Selective Inhibitors of Cyclooxygenase-2." Exp. Opin. Ther. Patents (1997) 7(1), pgs. 55-62.
	27	Roy, P., "A New Series of Selective Cox-2 Inhibitors: 5,6-Diarylthiazolo [3,2-b][1,2,2,4] Triazoles," Bioorganiz & Med. Chem. Ltrs., Vol. 7, No. 1, 1997, pp. 57-62.
	28	Therien, Michael, "Synthesis and Biological Evaluation of 5, 6-Diarylimidazo[2.1-b]Thiazole As Selective Cox-2 Inhibitors, Bioorganic & Med. Chem. Ltrs., Vol. 7, No. 1, 1997, pp. 47-52.
	29	Akahane, Atsushi, "Discovery of 6-Oxo-3-(2-Phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinebutanoic Acid (FR 838): A Novel Xanthine Adenosine A ₁ Receptor Antagonist with Potent Diuretic Activity," Journal of Medicinal Chemistry, Vol. 42, No. 5, 1999, pp. 779-783.
	30	Talley, John J., 5 Selective Inhibitors of Cyclooxygenase-2 (COX-2) Progress in Medicinal Chemistry, Vol. 36, (1999): pp. 201-234

Continue on page 2

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.	

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTORNEY DOCKET NO. PU4959USW		SERIAL NO. 10/530,101	
				APPLICANT: GUDMUNDSSON et al.			
				FILING Date: April 1, 2005		GROUP 1614	
U.S. PATENT DOCUMENTS							
Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	31	4,576,952	Mar. 18, 1986	Hurst et al.			
	32	4,621,089	Nov. 4, 1986	Ward et al.			
	33	4,670,432	June 2, 1987	Ward et al.			
	34	5,204,346	Apr. 20, 1993	Shiokawa et al.			
	35	5,234,930	Apr. 10, 1993	Skiokawa et al.			
	36	6,207,675	Mar. 27, 2001	Carry et al.			
	37	5,773,530	June 30, 1998	Akahane et al.			
Continue on page							
FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Subclasses	Translation Yes No
	38	EP 0 364 204 A1	Oct. 10, 1989	WIPO			
	39	EP 0 467 248 B1	July 13, 1991	Europe			
	40	WO 96 06840	Mar. 7, 1996	WIPO			
	41	WO 96 31509	Oct. 10, 1996	WIPO			
	42	WO 99 12930	Mar. 18, 1999	WIPO			
	43	WO 96 21667	July 18, 1996	WIPO			
	44	WO 02 18382	Mar. 7, 2002	WIPO			
	45	WO 02 48147	June 20, 2002	WIPO			
	46	WO 03/00682	Jan. 3, 2003	WIPO			
	47	WO 00/26216	May 11, 2000	WIPO			
	48	WO 99/58523	Nov. 18, 1999	WIPO			
	49	WO 00/52008	Sept. 8, 2000	WIPO			
	50	WO 01/00615	Jan. 4, 2001	WIPO			
	51	WO 99/59585	Nov. 25, 1999	WIPO			
	52	WO 02/048148	June 20, 2002	WIPO			
	53	EP 0 497 258 A2	Jan. 28, 1992	Europe			
	54	FR 2 757 059	June 19, 1998	France			X abstract only
Continue on page							
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
	55	Boehm, J.C., et al. "1-Substituted 4-Aryl-5-pyridinylimidazoles: A New Class of Cytokine Suppressive Drugs with Low 5-Lipoxygenase and Cyclooxygenase Inhibitory Potency." J. Med. Chem. 1996, 39, pgs. 3929-3937.					
	56	Hanson, G.J., et al. "Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis, Inhibitors of p38 kinase." Expert Opinion Ther. Patents, 1997, 7(7):729-733.					
	57	Roizman, B., et al. "The Family Herpesviridae: A Brief Introduction." Fields Virology, Vol. 2, 4 th Edition, pp. 2381-2397.					
	58	Douglas, R.G., Jr. "Introduction to Viral Diseases." Cecil Textbook of Medicine, 20 th Edition, Vol. 2, pp. 1739-47, 1996.					
	59	Razonable, R.R., et al. "Herpes Virus Infections in Transplant Recipients: Current Challenges in the Clinical Management of Cytomegalovirus and Epstein-Barr Virus Infections." PubMed Abstract, Herpes 10(3):60-5, December 2003.					
	60	Bosserey, A., et al. "What's New in Vaccines Against Herpes Simplex Infections." PubMed Abstract, Pathol. Biol (Paris) 50(*):483-92, October 2002.					
Continue on page							
EXAMINER					DATE CONSIDERED		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							